These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35667838)

  • 1. Association of Structural Measurements of Brain Reserve With Motor Progression in Patients With Parkinson Disease.
    Wang L; Wu P; Brown P; Zhang W; Liu F; Han Y; Zuo CT; Cheng W; Feng J
    Neurology; 2022 Sep; 99(10):e977-e988. PubMed ID: 35667838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Cortical and Subcortical Microstructure With Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease.
    Wang L; Zhou C; Zhang W; Zhang M; Cheng W; Feng J
    Neurology; 2023 Jul; 101(3):e300-e310. PubMed ID: 37202161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's Disease.
    Bartl M; Dakna M; Schade S; Wicke T; Lang E; Ebentheuer J; Weber S; Trenkwalder C; Mollenhauer B
    J Parkinsons Dis; 2022; 12(1):437-452. PubMed ID: 34719511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
    Davis MY; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Chen-Plotkin A; Van Deerlin VM; Quinn JF; Chung KA; Peterson-Hiller AL; Rosenthal LS; Dawson TM; Albert MS; Goldman JG; Stebbins GT; Bernard B; Wszolek ZK; Ross OA; Dickson DW; Eidelberg D; Mattis PJ; Niethammer M; Yearout D; Hu SC; Cholerton BA; Smith M; Mata IF; Montine TJ; Edwards KL; Zabetian CP
    JAMA Neurol; 2016 Oct; 73(10):1217-1224. PubMed ID: 27571329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study.
    Sun X; Dou K; Xue L; Xie Y; Yang Y; Xie A
    Clin Transl Sci; 2024 Jan; 17(1):e13720. PubMed ID: 38266062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
    Lang AE; Eberly S; Goetz CG; Stebbins G; Oakes D; Marek K; Ravina B; Tanner CM; Shoulson I;
    Mov Disord; 2013 Dec; 28(14):1980-6. PubMed ID: 24123383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease.
    Wang L; Zhang W; Liu F; Mao C; Liu CF; Cheng W; Feng J
    JAMA Netw Open; 2022 Jul; 5(7):e2223821. PubMed ID: 35881392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale.
    Stebbins GT; Goetz CG; Burn DJ; Jankovic J; Khoo TK; Tilley BC
    Mov Disord; 2013 May; 28(5):668-70. PubMed ID: 23408503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    van den Heuvel L; Evers LJW; Meinders MJ; Post B; Stiggelbout AM; Heskes TM; Bloem BR; Krijthe JH
    Mov Disord; 2021 Feb; 36(2):407-414. PubMed ID: 33107639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of striatal dopamine transporter binding with motor and non-motor symptoms in early Parkinson's disease.
    Yang Z; Xie Y; Dou K; Yang L; Xie A
    Clin Transl Sci; 2023 Jun; 16(6):1021-1038. PubMed ID: 36915231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of specific biotypes in patients with Parkinson disease and disease progression.
    Wang L; Cheng W; Rolls ET; Dai F; Gong W; Du J; Zhang W; Wang S; Liu F; Wang J; Brown P; Feng J
    Neurology; 2020 Sep; 95(11):e1445-e1460. PubMed ID: 32817178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?
    Simuni T; Caspell-Garcia C; Coffey C; Lasch S; Tanner C; Marek K;
    Parkinsonism Relat Disord; 2016 Jul; 28():62-7. PubMed ID: 27132498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
    Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
    JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
    Parashos SA; Luo S; Biglan KM; Bodis-Wollner I; He B; Liang GS; Ross GW; Tilley BC; Shulman LM;
    JAMA Neurol; 2014 Jun; 71(6):710-6. PubMed ID: 24711047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.